Global Cancer Antibody Combinations Market Opportunity and Clinical Trials Insight 2028

  • No. of Pages: 1500
  • Publish Date: December-2023
  • Category: Pharmaceutical and Healthcare
Electronic Access - Single User License
CD-ROM Mail Delivery
Hard Copy Mail Delivery
Electronic Access - Multi-User License

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only



Global Cancer Antibody Combinations Market Opportunity and Clinical Trials Insight 2028 Report Findings and Highlights:


  • Global Cancer Antibody Combinations Market Opportunity: > USD 50 Billion By 2028
  • Insight On Approved Cancer Antibody Combinations In Market: > 65 Antibodies Combinations
  • Insight On Cancer Antibody Combinations In Clinical Trials: > 490 Antibodies Combinations
  • Patent, Pricing, and Dosage Insight On Approved Combinations
  • Global Cancer Antibody Combinations Clinical Trials Insight  By Company, Indication and Phase
  • Global Antibody Combinations Market Development by Region and Indications


Combinations Included In Report:


  • Approved Antibody - Antibody Combinations
  • Approved Antibody - Small Molecule Inhibitors Combinations
  • Approved Antibody - Immunomodulatory Agents Combinations
  • Approved Antibody - Chemotherapy Combinations
  • Approved Antibody - Mixed Combinations
  • Ongoing Clinical Trials Combination With Bispecific Antibodies, Cancer Vaccines, Cell Therapies, Radiotherapy


In the recent years, the landscape of medical therapeutics has witnessed a paradigm shift with the emergence of antibody combination therapies, a dynamic approach that intertwines the precision of antibodies to target specific molecules with the synergistic benefits of different types of antibodies. By merging different types of monoclonal antibodies with other therapeutic agents, numerous pathways that are involved in the pathogenesis of cancer may be targeted simultaneously, thereby, possibly leading to additive or else synergistic effects. Theoretically, the combinations of antibodies are very suitable approach that can be employed for the treatment of cancer modalities because of the fact that the antibody combination therapy aids to limit overlapping toxicity along with lack of pharmacokinetic (PK) interactions.


The hypothesis of combining antibodies with other therapeutic agents began in the late 1990s when the researchers together with scientists amplified the preclinical testing that includes a combinations of monoclonal antibodies (mAb) with chemotherapy, radiotherapy or any other therapeutic agents in order to address the occurrence of drug resistant strains or the escape mechanism for observed in cancer malignancies. The main purpose of these investigations was to expand the therapeutic index as well as the potential of mAbs. Advantages such as amended efficiency, diminished toxicities, delayed development of therapy or drug resistances in addition dose reduction were observed in the preclinical studies that come along with antibody combinations.


In dichotomy with the conventional treatments such as chemotherapy and radiotherapy, which clenches the possibility to damage healthy cells, with the arrival of antibody combination therapies has transformed the landscape of targeted medicine. As of now, multiple antibody combination therapies such as Phesgo, Herceptin with Perjeta, Ramucirumab with docetaxel, atezolizumab, Bevacizumab with chemotherapy, atezolizumab and bevacizumab, and ipilimumab and nivolumab etc have been approved by the FDA, EMA, NICE and others for the treatment of diverse type of cancers.


In the realm of cancer therapy, the preliminary clinical development for the domain of antibody combinations were focused on creating anti-PD-1, anti-CTLA-4 and anti-PD-L1 monoclonal antibody (mAb) combinations, there has been modern improvement observed in harnessing the potential of mAb in conjugation with chemotherapy or with various oral small molecule multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) or platelet derived growth factor receptor (PDGFR) as the first-line treatment for multiple types of cancer like advanced solid tumors, hematological cancer, etc. Zhejiang University based in China is conducting clinical studies in which the combination of anti-PD-1 antibody with Donafenib, multikinase inhibitor, is ongoing to evaluate the safety and efficacy of the treatment regimen.


Another pharmaceutical company based in China, Chia Tai Tianqing Pharmaceutical Group reported another combination of anti-PD-1 antibody, Penpulimab with multi targeted receptor TKI, Anlotinib for the treatment of patients suffering from hepatocellular cancer (HCC). The primary goal of this study is to assess the effectiveness of combined treatment regimen for adjuvant therapy. It is a randomized, double-blind, placebo-controlled, multicenter phase 3 study which was initiated in May 2023 and is expected to be complete by December 2026.


Hitherto, the clinical pipeline for the domain of antibody combination therapy for treating cancer modalities majorly consists of immune checkpoint inhibitors, such as CTLA-4, PD-1 and PD-L1, PP2A inhibitors, CDK4/6 inhibitors, mAbs targeting HER 2, TIGIT mAbs, bispecific antibodies, CAR T cell therapies, antibody drug conjugates, and others. It is expected that the imminent years will certainly witness innovative antibody combinations for the treatment of cancer malignancies as evident from augmenting interest in pharmaceutical sectors and fostering FDA designations to novel combination therapy. For instance, in August 2023, Agenus was granted the Fast Track Designation for its innovative antibody combination, botensilimab (AGEN1181) and balstilimab (AGEN2034) for the treatment of colorectal cancer patients.  


With the increasing prevalence of cancer types at an alarming gait urges the need to develop better as well as innovative antibody combination therapies which could provide cure in addition to anticipation amidst the populace suffering from cancer across the globe. Furthermore, an inclining market trend towards utilizing the realm of antibody combination has been observed due to involvement of various stakeholders from pharmaceutical and biotech companies such as Pfizer, Bristol-Myers Squibb, AstraZeneca, Daiichi Sankyo, Taizhou EOC Pharma, Agenus, Novartis, Celldex Therapeutics and Merck. With the current market scenario, the future of the antibody combination market looks promising and is expected to multiple further as evident from the growing clinical trials, rising research and development and involvement of various stakeholders in the domain.  



Need custom market research solution? We can help you with that too.